Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
about
Targeted Delivery Systems for Molecular Therapy in Skeletal DisordersKY-62, a polyene analog of amphotericin B, for treatment of murine candidiasisDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Lipid-based amphotericin B for the treatment of fungal infections.Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion.Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.Nanodisks derived from amphotericin B lipid complex.Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovaniDistribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.Population pharmacokinetics of amphotericin B lipid complex in neonates.Nanopharmaceuticals (part 1): products on the market.Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsComparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.Carrier effects on biological activity of amphotericin B.Treatment of leishmaniasis in HIV-positive patients.Antifungal pharmacokinetics and pharmacodynamicsPharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animalsComparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipidLiposomal amphotericin B: clinical experience and perspectives.Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery.An update on the use of antifungal agents.Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.Bone marrow-targeted liposomal carriersThe use of antifungal therapy in neonatal intensive care.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections?Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.
P2860
Q26752158-0CBFA8F1-F22C-49C6-A6A4-C12C17876AA5Q28379319-590934EB-3423-4D4A-A9BA-4DAA9580BBB9Q30275257-DA1C55F3-F561-488C-9895-6F0DB226CAA3Q33604227-16C1C045-8C38-428F-8616-3EEED4FE8A35Q33689514-DEBF750B-BE7A-479B-A784-357926458EA9Q33691165-BE291B52-B901-45CB-A873-D25F628BB1A2Q33692176-B68922DC-46A9-42C4-B1BD-57FF5C2BED81Q33946918-B8DF2538-7391-44F0-A43D-CA5675A85D3FQ33955428-47B4B763-22DB-4D13-9EBB-A8E181DF5020Q33976111-29DD9E9C-B1CA-42EB-B630-A16B75B69F58Q33978764-A5A640BB-A68F-4DEB-B77E-20EC320BA2CCQ33980180-2BB960D2-39F9-4CE4-8524-8F04E708DAD3Q33980885-580B4D53-B2D5-4421-9B7D-97D79C2499AFQ34228332-3074F9C1-FE95-4CD4-A79A-CF474A5CF0D0Q34230175-42B0A906-0A27-4434-83C2-4265DECB5511Q34294886-83A47E2A-62EA-474F-A5F4-F07EBC2C1022Q34294904-10F9F23C-A510-49DE-A36E-CA4BE5BC9582Q34335230-D5E4674C-8F94-4DBB-8896-230DB668F06FQ34352186-E0E49F0F-204F-4D1A-98B8-3B044BED6557Q35118084-8072A364-C09E-4A25-BE69-7DAF22D06165Q35122944-FE133B06-1DA6-497F-A253-D0B9AD683750Q35124422-34FDAEF5-E8C4-4616-8D36-7D13608CB748Q35134721-D5ADDE8E-2C25-42AF-8803-DF6664886616Q35136556-567CED60-E3AC-4299-8F2E-B4D9DBC60F37Q35138378-F4CAD497-8A83-4513-B9E9-1BA63D2578EFQ35372581-21095CD1-ADBA-4500-8FA1-E6947EC86027Q35609052-A63C5CD7-5407-4B3D-B70B-09CDCDC24E1CQ35663841-00A445BC-9BF6-443B-90F6-6BF5048C2064Q35685280-FC9C5E37-8F34-42D7-87D2-6EF36066899BQ35758926-A641F1EE-4673-4807-A98B-8DDAAFB068C4Q35891310-6EC3C49E-B636-40E6-944C-3391DBD8A103Q36140647-BD1B937C-72BD-4C61-9DA2-B4056CC814C6Q36349667-ADF6339F-DE6D-43F5-85A4-48A854054EEEQ36724783-AC73785B-14EB-407E-AA1E-E373E613AE7FQ37059900-68CF577F-D578-43F2-8910-3FF058A586F4Q37833107-7416AFFB-5343-49C8-BA9D-6B86FBB4B9A1Q37985070-A1121A2C-F9EF-4440-B415-FAEF892174C0Q38215682-9723A2F2-E44B-4671-B00E-DF702B7BC4F6Q38561855-839D68A0-7193-43E6-9813-84DBD58DD040Q38653256-0D4F0ADA-E76C-44F0-B0EE-D3663E7E7563
P2860
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@ast
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@en
type
label
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@ast
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@en
prefLabel
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@ast
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@en
P2093
P1476
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
@en
P2093
Bakker-Woudenberg IA
Crommelin DJ
Janknegt R
de Marie S
P304
P356
10.2165/00003088-199223040-00004
P577
1992-10-01T00:00:00Z
P5875
P6179
1041292032